We offer a comprehensive range of monoclonal and polyclonal antibodies to key tumor and leukemia biomarkers, for research purposes as well as diagnostic assay development.
The identification of cancer markers using antibodies is a widely used strategy in cancer diagnostics, screening and research.
Tumor marker-specific antibodies can be used to detect elevated quantities of tumor markers in patients' blood, urine or tissue, for cancer diagnosis and prognostic evaluation. The mostly widely accepted cancer marker of this kind is the prostate specific antigen (PSA) used in the diagnosis of prostate cancer.
Some cancer markers are common to a few types of cancers, such as HER2, commonly used for breast cancer as well as advanced stomach cancer diagnosis, and human chorionic gonadotropin (β-hCG), where the blood level of β-hCG is elevated in patients with some types of testicular and ovarian cancers, and in choriocarcinoma.
Another group of cancer biomarkers are CD (cluster of differentiation) markers, an extremely diverse series of membrane proteins predominantly expressed on the leukocyte cell surface, and other cell types including endothelial, stem and dendritic cells. CD markers are used to classify white blood cells (WBC) and are especially important for diagnosis of lymphomas and leukemias. CD marker-specific antibodies have been widely used for cell sorting, phenotyping, and blood cancer diagnosis.
In addition, CD markers have become significantly important for cancer treatment. Some therapeutic antibody drugs have been designed to target cells that have a particular type of CD marker (e.g, rituximab to CD20 for lymphomas and leukemia treatment; alemtuzumab to CD52 for chronic lymphocytic leukemia and T-cell lymphoma treatment).